F-star?is an oncology-focused biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve the standard of care for patients.
The company’s Modular Antibody Technology? allows developers to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. It combines the power of our Fcab? technology with traditional antibodies to identify the most appropriate target combinations, thus providing the opportunity to deliver products with the greatest therapeutic advantage to patients.
Schwarzenbergplatz 7,
A-1030 Vienna, Austria
Web:?F-star
Advertisement #5
